» Articles » PMID: 37369396

Effectiveness of Inactivated COVID-19 Vaccines Against SARS-CoV-2 Infections Among Healthcare Personnel in Pakistan: a Test-negative Case-control Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2023 Jun 27
PMID 37369396
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: During the COVID-19 pandemic, several vaccines that were efficacious in randomised controlled trials were authorised for mass vaccination. In developing countries, inactivated vaccines were widely administered. While inactivated vaccines have been deemed effective in reducing disease severity, for healthcare personnel (HCP), effectiveness against SARS-CoV-2 infections is essential to reduce the risk to vulnerable patients and ensure a stable healthcare workforce. There are limited studies examining inactivated vaccines' effectiveness against SARS-CoV-2 variants of concern (VOCs) in real-world settings. We estimated the effectiveness of inactivated vaccines (BBIBP-CorV and CoronaVac) against reverse transcription PCR (RT-PCR)-confirmed SARS-CoV-2 infections among HCP in the setting of emerging SARS-CoV-2 VOCs in Pakistan.

Design: A retrospective matched, test-negative case-control analysis using existing data from an Employee Health database on HCP at a large, private healthcare system in Pakistan.

Participants: 4599 HCP were tested between 1 April and 30 September 2021. Each case (PCR positive) was matched to two to six controls (PCR negative) by the date of the RT-PCR test (±7 days) to reduce bias.

Primary And Secondary Outcome Measures: The primary outcome was vaccine effectiveness (VE) against SARS-CoV-2 infection. The secondary outcome was VE against symptomatic SARS-CoV-2 infection. Per cent VE was calculated using (1-OR)*100, with the OR of getting a PCR-confirmed SARS-COV-2 infection estimated using conditional logistic regression, after adjusting for age, gender, work area and history of SARS-CoV-2 infection.

Results: Inactivated vaccines were ineffective against SARS-CoV-2 infections after receiving the first dose (VE 17%, 95% CI -10, 39; p=0.261). They showed modest effectiveness ≥14 days after the second dose against SARS-CoV-2 infections (VE 30%, 95% CI 7, 48; p=0.015) and symptomatic SARS-CoV-2 infections (VE 33%, 95% CI 6, 52; p=0.002).

Conclusions: Inactivated vaccines show modest effectiveness against SARS-CoV-2 infections in the setting of emerging VOCs. This builds a strong case for boosters and/or additional vaccination.

Citing Articles

Biases in COVID-19 vaccine effectiveness studies using cohort design.

Agampodi S, Tadesse B, Sahastrabuddhe S, Excler J, Kim J Front Med (Lausanne). 2024; 11:1474045.

PMID: 39540039 PMC: 11557388. DOI: 10.3389/fmed.2024.1474045.


Shift in SARS-CoV-2 variants of concern from Delta to Omicron was associated with reduced hospitalizations, increased risk of breakthrough infections but lesser disease severity.

Mwendwa F, Kanji A, Bukhari A, Khan U, Sadiqa A, Mushtaq Z J Infect Public Health. 2024; 17(6):1100-1107.

PMID: 38714122 PMC: 11142923. DOI: 10.1016/j.jiph.2024.04.025.


Exploring the relationship between SARS-CoV-2 variants, illness severity at presentation, in-hospital mortality and COVID-19 vaccination in a low middle-income country: A retrospective cross-sectional study.

Mushtaq M, Nasir N, Mahmood S, Khan S, Kanji A, Nasir A Health Sci Rep. 2023; 6(12):e1703.

PMID: 38045627 PMC: 10690835. DOI: 10.1002/hsr2.1703.


Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population.

Bahce Y, Acer O, Ozudogru O Curr Microbiol. 2023; 80(6):206.

PMID: 37160453 PMC: 10169106. DOI: 10.1007/s00284-023-03322-z.

References
1.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

2.
Patel M, Bergeri I, Bresee J, Cowling B, Crowcroft N, Fahmy K . Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021; 39(30):4013-4024. PMC: 8166525. DOI: 10.1016/j.vaccine.2021.05.099. View

3.
Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell B . The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(49):1857-1859. PMC: 7737687. DOI: 10.15585/mmwr.mm6949e1. View

4.
Jeewandara C, Aberathna I, Pushpakumara P, Kamaladasa A, Guruge D, Wijesinghe A . Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine. Immun Inflamm Dis. 2022; 10(6):e621. PMC: 9091995. DOI: 10.1002/iid3.621. View

5.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani M, Abdulrazzaq N . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021; 326(1):35-45. PMC: 8156175. DOI: 10.1001/jama.2021.8565. View